← Leaderboards
Paul F Bates
University Of Pennsylvania
$14,487,725
Attributed
$15,453,537
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,453,537 · 14
By mechanism
R01$7,730,678 · 5
T32$3,329,398 · 1
U01$1,639,161 · 1
R21$1,510,443 · 3
R41$532,169 · 1
U54$400,657 · 2
Top collaborators
- Matthew D. Weitzman5 shared
- Luis Cocka2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Ronald N. Harty$14,036,721
- Susan R. Weiss$24,407,392
- Alexander J Travis$8,423,991
- Benhur Lee$26,036,912
- Tuhina Srivastava$85,874
Others in their field
Top investigators on “Glycoproteins”
- Dennis R. Burton · Scripps Research Institute$211,788,189
- Joseph G Sodroski · University Of Pennsylvania$47,423,604
- Kartik Chandran · Albert Einstein College Of Medicine$41,665,810
- Erica Ollmann Saphire · Scripps Research Institute$32,718,575
- Robert F Garry · Scripps Research Institute, The$32,430,244
- James E Crowe · Vanderbilt University Medical Center$32,099,289
Research focus
GlycoproteinsEbola VirusVirus DiseasesViralPathogenInfectionVirusVaccinesSurfaceReportingAntiviral AgentsInterferonsPathologyVirionTrainingProgramsVirologyAnimal ModelVesicular Stomatitis Indiana VirusImmune ResponseGenesVectorResponseMembrane Glycoproteins
Grant awards (50)
Development of vaccines targeting a tick-borne phlebovirus$577,453
R01 · FY2024 · AI · contact PI
Development of recombinant VSV vaccines for emerging bunyaviruses$276,715
R41 · FY2024 · AI · contact PI
Development of vaccines targeting a tick-borne phlebovirus$581,039
R01 · FY2023 · AI · contact PI
Training in Virology$290,481
T32 · FY2023 · AI · contact PI
Development of recombinant VSV vaccines for emerging bunyaviruses$255,454
R41 · FY2023 · AI · contact PI
Development of vaccines targeting a tick-borne phlebovirus$577,515
R01 · FY2022 · AI · contact PI
Training in Virology$255,100
T32 · FY2022 · AI · contact PI
Development of vaccines targeting a tick-borne phlebovirus$215,821
R01 · FY2022 · AI · contact PI
Development of vaccines targeting a tick-borne phlebovirus$548,028
R01 · FY2021 · AI · contact PI
Training in Virology$290,509
T32 · FY2021 · AI · contact PI
A VSV vectored vaccine for emergent tick-born phleboviruses$202,917
R21 · FY2021 · AI · contact PI
Development of vaccines targeting a tick-borne phlebovirus$535,986
R01 · FY2020 · AI · contact PI
Training in Virology$297,369
T32 · FY2020 · AI · contact PI
A VSV vectored vaccine for emergent tick-born phleboviruses$243,000
R21 · FY2020 · AI · contact PI
Training in Virology$265,996
T32 · FY2019 · AI · contact PI
Discovering host factors impacting ZIKV infection via forward genetic screens$195,138
R21 · FY2018 · AI · contact PI
Training in Virology$247,373
T32 · FY2017 · AI · contact PI
Discovering host factors impacting ZIKV infection via forward genetic screens$235,388
R21 · FY2017 · AI · contact PI
Training in Virology$260,021
T32 · FY2016 · AI · contact PI
Training in Virology$254,466
T32 · FY2015 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$410,485
R01 · FY2014 · AI · contact PI
Training in Virology$209,586
T32 · FY2014 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$420,649
R01 · FY2013 · AI · contact PI
Training in Virology$247,908
T32 · FY2013 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$444,890
R01 · FY2012 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$8,870
R01 · FY2012 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$391,155
R01 · FY2011 · AI · contact PI
Training in Virology$354,701
T32 · FY2011 · AI · contact PI
Interactions of Ebola virus glycoproteins with host cells$394,201
R01 · FY2010 · AI · contact PI
Training in Virology$355,888
T32 · FY2010 · AI · contact PI
Small molecule inhibitors targeting filoviral infections$288,499
U54 · FY2009 · AI · contact PI
Therapeutics targeting cathepsin-activated viral entry$473,753
U01 · FY2008 · AI · contact PI
Developing Cathepsin Inhibitors as Therapeutics for Emerging Viral Infections$112,158
U54 · FY2008 · AI · contact PI
Therapeutics targeting cathepsin-activated viral entry$575,911
U01 · FY2007 · AI · contact PI
Therapeutics targeting cathepsin-activated viral entry$589,497
U01 · FY2006 · AI · contact PI
Analysis of the SARS Virus S glycoproteins$317,000
R21 · FY2005 · AI
Analysis of the SARS Virus S glycoproteins$317,000
R21 · FY2004 · AI
CHARACTERIZATION OF EBOLA VIRAL GYLCOPROTEINS$274,584
R01 · FY2003 · AI
LENTIVIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$279,252
R01 · FY2002 · DK
FUNCTIONAL ANALYSIS OF RSV ENVELOPE GLYCOPROTEIN$269,651
R01 · FY2002 · CA
CHARACTERIZATION OF EBOLA VIRAL GYLCOPROTEINS$238,916
R01 · FY2002 · AI
CORE--VIRUS VECTOR FACILITY$103,677
P01 · FY2002 · CA
LENTIVIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$271,118
R01 · FY2001 · DK
FUNCTIONAL ANALYSIS OF RSV ENVELOPE GLYCOPROTEIN$262,393
R01 · FY2001 · CA
CHARACTERIZATION OF EBOLA VIRAL GYLCOPROTEINS$258,821
R01 · FY2001 · AI
CORE--VIRUS VECTOR FACILITY$103,677
P01 · FY2001 · CA
LENTIVIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$263,222
R01 · FY2000 · DK
FUNCTIONAL ANALYSIS OF RSV ENVELOPE GLYCOPROTEIN$255,347
R01 · FY2000 · CA
CHARACTERIZATION OF EBOLA VIRAL GYLCOPROTEINS$251,282
R01 · FY2000 · AI
CORE--VIRUS VECTOR FACILITY$103,677
P01 · FY2000 · CA